Emulate, Inc.
- Sep 7, 2021 · D · $57,499,997 sold of $57,499,997 · 7 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
- Mar 23, 2020 · D · $19,275,000 sold of $20,000,000 · 9 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
- Aug 16, 2019 · D · $27,994,991 sold of $50,000,000 · 8 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
- Jun 21, 2018 · D · $35,999,998 sold of $35,999,998 · 41 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Nov 9, 2017 · D · $745,750 sold of Indefinite · 4 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Mar 28, 2016 · D · $28,750,000 sold of $45,000,000 · 10 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Jul 28, 2014 · D · $12,000,000 sold of $12,000,000 · 4 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
Raised $57.5M from 41 investors (100% of the $57.5M target) as of the latest filing. Daniel is listed as executive officer, director on 7 filings for this deal.
Sources
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.